The study evaluated 10 kidney transplant recipients (KTRs) with parvovirus B19 (B19V) infection at a single center in India from January 2021 to February 2025. Infection occurred in 8.5% of 117 KTRs with a median onset of 2–62 weeks after transplantation. All patients (100%) had fatigue and hypoproliferative anemia with reticulocyte counts below 1%, with 30% also having leukopenia and thrombocytopenia. The mean decrease in hemoglobin was 3.72 ± 1.22 g/dL (p < 0.001). Treatment included reduction of immunosuppression, intravenous immunoglobulin (IVIg) in 60% of patients with recovery within 4 weeks, and Desidustat in all; 8 patients required red blood cell transfusions (1–8 units). Two patients died of other severe infections. Early PCR diagnosis and targeted treatment lead to favorable outcomes in refractory anemia.